Pulmonary sclerosing pneumocytoma: clinical features and prognosis

Zheng, Quan; Zhou, Jian; Li, Guangchen; Man, Siu Shing; Lin, Zhangyu; Wang, Tengyong; Chen, Boran; Lin, Feng Li

doi:10.1186/s12957-022-02603-4

Cited by 16 publications

(22 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At this time, it appears that a minimally invasive sublobar resection is an appropriate surgical approach for small, peripherally-located PSPs, while minimally invasive lobectomy should be the choice approach for larger tumors or those that are more centrally-located with greater potential for lymph node metastasis or recurrence [ 1 ]. However, further research in larger cohorts comparing the two approaches longitudinally are needed to clearly define these recommendations.…”

Section: Clinical Discussionmentioning

confidence: 99%

“…Pulmonary sclerosing pneumocytoma (PSP), formerly known as sclerosing hemangioma of the lung, is a rare tumor of the lung first described by Leibow and Hubbell in 1956 [ 1 , 2 ]. Here we present a 48-year old woman with incidentally-discovered PSP treated with a right video-assisted thoracic surgery (VATS) middle lobectomy and mediastinal lymph node dissection (MLND) and review the literature surrounding this rare diagnosis.…”

Section: Introduction and Importancementioning

confidence: 99%

Section: Introduction and Importancementioning

confidence: 99%

“…PSP originates from the respiratory epithelium and is most likely derived from type II pneumocytes [ 1 , 4 , 5 ]. PSP is generally asymptomatic [ 6 ] and is usually benign in nature, but carries the potential to have malignant characteristics such as lymph node metastasis or local recurrence [ 1 , 7 , 8 ]. Additionally, this rare mass is frequently mistaken for lung cancer malignancies upon initial imaging due to diagnostic difficulties, as many of the signs seen on imaging are non-specific [ 9 , 10 ].…”

Section: Introduction and Importancementioning

confidence: 99%

See 3 more Smart Citations

Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report

Barnes

Wile

Banks

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Section: Clinical Discussionmentioning

confidence: 99%

Section: Introduction and Importancementioning

confidence: 99%

Section: Introduction and Importancementioning

confidence: 99%

Section: Introduction and Importancementioning

confidence: 99%

See 2 more Smart Citations

Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report

Barnes

Wile

Banks

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

“…Pulmonary Sclerosing Pneumocytoma (PSP) is a relatively uncommon benign tumor of the lung with potential for malignant transformation that is manifested most commonly by metastasis to regional lymph nodes (Zheng et al, 2022). PSP was first reported by Liebow in 1956 (Liebow andHubbell, 1956), and shows a striking female predominance (female to male ratio 5:1) (Kalhor et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics

Peterson²,

Shin³

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Background: Pulmonary Sclerosing Pneumocytoma (PSP) is a rare tumor of the lung with a low malignant potential that primarily affects females. Initial studies of PSP focused primarily on analyzing features uncovered using conventional X-ray or CT imaging. In recent years, because of the widespread use of next-generation sequencing (NGS), the study of PSP at the molecular-level has emerged.Methods: Analytical approaches involving genomics, radiomics, and pathomics were performed. Genomics studies involved both DNA and RNA analyses. DNA analyses included the patient’s tumor and germline tissues and involved targeted panel sequencing and copy number analyses. RNA analyses included tumor and adjacent normal tissues and involved studies covering expressed mutations, differential gene expression, gene fusions and molecular pathways. Radiomics approaches were utilized on clinical imaging studies and pathomics techniques were applied to tumor whole slide images.Results: A comprehensive molecular profiling endeavor involving over 50 genomic analyses corresponding to 16 sequencing datasets of this rare neoplasm of the lung were generated along with detailed radiomic and pathomic analyses to reveal insights into the etiology and molecular behavior of the patient’s tumor. Driving mutations (AKT1) and compromised tumor suppression pathways (TP53) were revealed. To ensure the accuracy and reproducibility of this study, a software infrastructure and methodology known as NPARS, which encapsulates NGS and associated data, open-source software libraries and tools including versions, and reporting features for large and complex genomic studies was used.Conclusion: Moving beyond descriptive analyses towards more functional understandings of tumor etiology, behavior, and improved therapeutic predictability requires a spectrum of quantitative molecular medicine approaches and integrations. To-date this is the most comprehensive study of a patient with PSP, which is a rare tumor of the lung. Detailed radiomic, pathomic and genomic molecular profiling approaches were performed to reveal insights regarding the etiology and molecular behavior. In the event of recurrence, a rational therapy plan is proposed based on the uncovered molecular findings.

show abstract

CT‐based radiomics for differentiating peripherally located pulmonary sclerosing pneumocytoma from carcinoid

Zhang,

Yang,

et al. 2024

Medical Physics

View full text Add to dashboard Cite

BackgroundPulmonary sclerosing pneumocytoma (PSP) and pulmonary carcinoid (PC) are difficult to distinguish based on conventional imaging examinations. In recent years, radiomics has been used to discriminate benign from malignant pulmonary lesions. However, the value of radiomics based on computed tomography (CT) images to differentiate PSP from PC has not been well explored.PurposeWe aimed to investigate the feasibility of radiomics in the differentiation between PSP and PC.MethodsFifty‐three PSP and fifty‐five PC were retrospectively enrolled and then were randomly divided into the training and test sets. Univariate and multivariable logistic analyses were carried to select clinical predictor related to differential diagnosis of PSP and PC. A total of 1316 radiomics features were extracted from the unenhanced CT (UECT) and contrast‐enhanced CT (CECT) images, respectively. The minimum redundancy maximum relevance and the least absolute shrinkage and selection operator were used to select the most significant radiomics features to construct radiomics models. The clinical predictor and radiomics features were integrated to develop combined models. Two senior radiologists independently categorized each patient into PSP or PC group based on traditional CT method. The performances of clinical, radiomics, and combined models in differentiating PSP from PC were investigated by the receiver operating characteristic (ROC) curve. The diagnostic performance was also compared between the combined models and radiologists.ResultsIn regard to differentiating PSP from PC, the area under the curves (AUCs) of the clinical, radiomics, and combined models were 0.87, 0.96, and 0.99 in the training set UECT, and were 0.87, 0.97, and 0.98 in the training set CECT, respectively. The AUCs of the clinical, radiomics, and combined models were 0.84, 0.92, and 0.97 in the test set UECT, and were 0.84, 0.93, and 0.98 in the test set CECT, respectively. In regard to the differentiation between PSP and PC, the combined model was comparable to the radiomics model, but outperformed the clinical model and the two radiologists, whether in the test set UECT or CECT.ConclusionsRadiomics approaches show promise in distinguishing between PSP and PC. Moreover, the integration of clinical predictor (gender) has the potential to enhance the diagnostic performance even further.

show abstract

Pulmonary sclerosing pneumocytoma: clinical features and prognosis

Cited by 16 publications

References 42 publications

Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report

Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report

An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics

CT‐based radiomics for differentiating peripherally located pulmonary sclerosing pneumocytoma from carcinoid

Contact Info

Product

Resources

About